Company Overview
SciSparc Ltd. operates as a clinical-stage pharmaceutical company dedicated to developing drugs grounded in cannabinoid therapies for specific neurological and psychiatric conditions. The company functions within the broader Healthcare sector, specifically inside the Biotechnology industry, where it focuses on advancing therapeutic programs rather than established commercial products. In terms of scale, SciSparc Ltd. maintains a market capitalization of $2.21M, generates annual revenue of $1.31M, and employs a workforce of just two individuals. These financial figures indicate a very small-cap entity with minimal operational footprint, suggesting the company is in an early stage of development where revenue generation is limited and the organization has not yet scaled to a significant market presence.
Financial Health
The company reported a revenue of $1.31M over the trailing twelve months, while posting a net income of $-6,480,000 and an EBITDA of $-7,029,000. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure dominated by high research and development expenses or other operating costs that far exceed current sales. Free cash flow is listed as N/A, which indicates that the company does not currently generate sufficient cash from operations to fund its activities without external capital injection, reflecting a lack of immediate financial flexibility. Regarding profitability margins, the gross margin stands at 38.7%, indicating that the company retains a significant portion of revenue after direct production costs; however, the operating margin is -569.5% and the profit margin is 0.0%, both of which signify that operating expenses and other costs have overwhelmed the gross profit, resulting in a loss on every dollar of revenue. The company's balance sheet shows N/A for total cash and N/A for debt, meaning specific liquidity and leverage figures are not publicly disclosed or available for analysis. Furthermore, the debt-to-equity ratio is N/A, current ratio is N/A, and return on assets is N/A, preventing a direct assessment of leverage or short-term liquidity based on standard comparative metrics. The return on equity is reported at -1281.5%, a metric that, while extreme, mathematically reflects the relationship between net loss and shareholder equity in a loss-making stage, rather than indicating effective management in the traditional sense of generating returns on invested capital.
Valuation Assessment
SciSparc Ltd. has a trailing P/E ratio of 0.00 and a forward P/E that is N/A, implying that the company does not currently have earnings to value against share price and that future earnings expectations have not yet been quantified in a standard multiple format. The price-to-book ratio is 0.03, which indicates that the market values the company at a fraction of its book value, suggesting a deep discount relative to the accounting value of its assets. The price-to-sales ratio is 1.69, and the EV/EBITDA is N/A; these alternative metrics suggest that the market is pricing the company primarily on its sales potential rather than profitability or enterprise value multiples typically used for mature firms. The stock has a 52-week high of $94.50 and a 52-week low of $3.60, meaning the current trading price sits significantly below the 52-week high, reflecting the high volatility and speculative nature of the asset in its current market range. The beta is 1.28, which indicates that the stock price is expected to be more volatile than the broader market, moving 28% more than the market index during periods of volatility.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is no historical growth data available to compare current performance against prior periods. Because the company has a net loss and no established dividend history, it does not pay dividends; consequently, the company reinvests its limited resources and any available earnings into its drug development programs rather than distributing income to shareholders. The absence of dividend yield and payout ratio data, combined with the N/A growth figures, summarizes an overall growth and income profile that relies entirely on future clinical success and capital raises to drive shareholder value, offering no current income stream. This profile is characteristic of early-stage biotechnology firms where capital allocation focuses exclusively on R&D and clinical trials to achieve regulatory approval.